Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SLRX save search
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-22 (Crawled : 20:00) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
| Email alert
Add to watchlist
business year update pharmaceuticals financial results
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: -0.02%
H: 7.98%
C: -1.93%
review update ongoing seclidemstat trials
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
Published: 2024-01-16 (Crawled : 13:00) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: 1.48%
H: 2.57%
C: -3.72%
patent pharmaceuticals protein
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Published: 2024-01-03 (Crawled : 13:30) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: 4.67%
H: 4.4%
C: -4.66%
treat seclidemstat trial
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Published: 2023-11-07 (Crawled : 14:00) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: 11.25%
H: 4.49%
C: -6.85%
fda seclidemstat meeting program
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
Published: 2023-08-10 (Crawled : 20:00) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: -2.69%
H: 5.49%
C: -3.33%
business update pharmaceuticals financial results
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
Published: 2023-08-08 (Crawled : 20:00) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: -2.29%
H: 0.0%
C: -7.85%
pharmaceuticals
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
Published: 2023-07-11 (Crawled : 12:20) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: 3.45%
H: 0.01%
C: -15.33%
sp-3164 fda drug clearance pharmaceuticals application trial
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
Published: 2023-06-12 (Crawled : 12:00) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: 6.06%
H: 0.0%
C: -5.71%
sp-3164 association pharmaceuticals preclinical protein
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Published: 2023-05-16 (Crawled : 20:00) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: 0.71%
H: 2.13%
C: 1.42%
nasdaq pharmaceuticals
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Published: 2023-05-12 (Crawled : 12:00) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: 0.71%
H: 3.55%
C: -2.84%
nasdaq pharmaceuticals
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update
Published: 2023-05-11 (Crawled : 12:20) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: 2.03%
H: 1.98%
C: -7.28%
business update pharmaceuticals financial results
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
Published: 2023-05-09 (Crawled : 12:00) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: 6.48%
H: 0.43%
C: -21.3%
fda seclidemstat trial
Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164
Published: 2023-05-01 (Crawled : 14:20) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: 2.25%
H: 0.55%
C: -1.65%
sp-3164 pharmaceuticals protein
Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting
Published: 2023-04-20 (Crawled : 14:20) - biospace.com/
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: -8.6%
H: 1.76%
C: -2.35%
sp-3164 association cancer pharmaceuticals research protein meeting
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference
Published: 2023-04-04 (Crawled : 22:00) - biospace.com/
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: -3.15%
H: 0.07%
C: -9.47%
conference pharmaceuticals research growth
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Published: 2023-03-27 (Crawled : 14:00) - biospace.com/
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: -1.9%
H: 0.48%
C: 0.48%
business year update pharmaceuticals financial results
Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting
Published: 2023-03-15 (Crawled : 15:00) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: 0.88%
H: 1.49%
C: -4.17%
pharmaceuticals research meeting association presentation cancer
Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: 0.0%
H: 0.0%
C: 0.0%
pharmaceuticals lung seclidemstat cancer in vitro
Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas
Published: 2023-02-16 (Crawled : 14:00) - globenewswire.com
SLRX | $0.499 1.2% 1.18% 43K
|
Commercial Services
|
| O: -2.68%
H: 3.21%
C: 2.29%
pharmaceuticals research cancer
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.